WSJ's blog on health and the business of health.

Visit WSJ.com: Health Blog

Vytoringate: Congress Investigates Exec s Stock Sale

Posted on January 22, 2008

Congress is pressing Merck and Schering-Plough for information on the timing of executive stock sales in the wake of the delayed release of results from the Enhance trial a long-awaited study whose results became public last week. The findings suggest the cholesterol drug Vytorin doesn t slow heart disease any better than a generic statin alone. Schering-Plough s stock has taken a beating since then (see 10-day chart). We have discovered that a Schering-Plough officer, Carrie Smith Cox, sold significant numbers of shares of Schering-Plough in the time between the end of the ENHA...

Original article link


cholesterol , heart disease